logo
#

Latest news with #LanceWilkes

Bernstein Keeps Their Buy Rating on Agilon Health (AGL)
Bernstein Keeps Their Buy Rating on Agilon Health (AGL)

Business Insider

time3 days ago

  • Business
  • Business Insider

Bernstein Keeps Their Buy Rating on Agilon Health (AGL)

In a report released today, Lance Wilkes from Bernstein maintained a Buy rating on Agilon Health (AGL – Research Report), with a price target of $7.50. The company's shares closed today at $2.16. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Wilkes covers the Healthcare sector, focusing on stocks such as UnitedHealth, Humana, and Elevance Health. According to TipRanks, Wilkes has an average return of -0.3% and a 42.86% success rate on recommended stocks. Currently, the analyst consensus on Agilon Health is a Hold with an average price target of $4.60.

Bernstein Sticks to Its Buy Rating for Centene (CNC)
Bernstein Sticks to Its Buy Rating for Centene (CNC)

Business Insider

time3 days ago

  • Business
  • Business Insider

Bernstein Sticks to Its Buy Rating for Centene (CNC)

Bernstein analyst Lance Wilkes maintained a Buy rating on Centene (CNC – Research Report) today and set a price target of $86.00. The company's shares closed today at $55.16. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Wilkes covers the Healthcare sector, focusing on stocks such as UnitedHealth, Humana, and Elevance Health. According to TipRanks, Wilkes has an average return of -0.3% and a 42.86% success rate on recommended stocks. In addition to Bernstein, Centene also received a Buy from Wells Fargo's Stephen Baxter in a report issued yesterday. However, on June 2, Barclays downgraded Centene (NYSE: CNC) to a Hold.

Molina Healthcare (MOH) Receives a Buy from Bernstein
Molina Healthcare (MOH) Receives a Buy from Bernstein

Business Insider

time3 days ago

  • Business
  • Business Insider

Molina Healthcare (MOH) Receives a Buy from Bernstein

In a report released today, Lance Wilkes from Bernstein maintained a Buy rating on Molina Healthcare (MOH – Research Report), with a price target of $414.00. The company's shares closed today at $296.88. Confident Investing Starts Here: According to TipRanks, Wilkes is a 2-star analyst with an average return of -0.3% and a 42.86% success rate. Wilkes covers the Healthcare sector, focusing on stocks such as UnitedHealth, Humana, and Elevance Health. In addition to Bernstein, Molina Healthcare also received a Buy from Wells Fargo's Stephen Baxter in a report issued yesterday. However, on June 3, Barclays maintained a Hold rating on Molina Healthcare (NYSE: MOH). Based on Molina Healthcare's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $11.15 billion and a net profit of $298 million. In comparison, last year the company earned a revenue of $9.93 billion and had a net profit of $301 million Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MOH in relation to earlier this year. Last month, Dale Wolf, a Director at MOH sold 1,500.00 shares for a total of $484,328.00.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store